ASC30_48_39FDC

Taipei, August 3, 2026 GlycoNex Inc. announced that the first patient has been successfully dosed in the first-in-human Phase...

San Francisco, August 3, 2026 AusperBio Therapeutics Inc. and Ausper Biopharma Co., Ltd. announced the initiation of patient dosing...

Hong Kong – August 3, 2026 Ascletis Pharma Inc. has initiated a global Phase III clinical development program for...